Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00476996
Registration number
NCT00476996
Ethics application status
Date submitted
18/05/2007
Date registered
22/05/2007
Date last updated
12/08/2019
Titles & IDs
Public title
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-a Therapy (SCRIPT)
Query!
Scientific title
A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-a Therapy
Query!
Secondary ID [1]
0
0
WA20495
Query!
Secondary ID [2]
0
0
ACT3986g
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SCRIPT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Leflunomide
Treatment: Drugs - Methotrexate
Treatment: Drugs - Ocrelizumab
Treatment: Drugs - Ocrelizumab
Treatment: Drugs - Placebo
Experimental: Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy - Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
Experimental: Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy - Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
Placebo Comparator: Placebo x 2 IV + Non-Biologic DMARD Therapy - Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
Treatment: Drugs: Leflunomide
Oral repeating dose
Treatment: Drugs: Methotrexate
Oral or parenteral repeating dose
Treatment: Drugs: Ocrelizumab
Intravenous repeating dose (200mg)
Treatment: Drugs: Ocrelizumab
Intravenous repeating dose (500mg)
Treatment: Drugs: Placebo
Intravenous repeating dose
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With American College of Rheumatology 20 (ACR20) Responses
Query!
Assessment method [1]
0
0
ACR20 response: greater than or equal to (=) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale [VAS]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.
Query!
Timepoint [1]
0
0
Weeks 24 and 48
Query!
Secondary outcome [1]
0
0
Percentage of Participants With a Major Clinical Response
Query!
Assessment method [1]
0
0
Major clinical response was defined as achieving an ACR70 response and maintaining this response for a consecutive period of at least 6 months.
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [2]
0
0
Percentage of Participants Achieving Disease Activity Score (DAS28) Remission
Query!
Assessment method [2]
0
0
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.
Query!
Timepoint [2]
0
0
Weeks 24 and 48
Query!
Secondary outcome [3]
0
0
Change in DAS28 From Baseline
Query!
Assessment method [3]
0
0
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10.
Query!
Timepoint [3]
0
0
Weeks 24 and 48
Query!
Secondary outcome [4]
0
0
Percentage of Participants With EULAR Response Rates of Good/ Moderate
Query!
Assessment method [4]
0
0
The EULAR response rate was based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none.
Query!
Timepoint [4]
0
0
Weeks 24 and 48
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving an ACR50 Response
Query!
Assessment method [5]
0
0
ACR50 response is defined as a = 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, Health Assessment Questionnaire with Disability Index (HAQ-DI), and C-Reactive Protein (CRP).
Query!
Timepoint [5]
0
0
Weeks 24 and 48
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving an ACR70 Response
Query!
Assessment method [6]
0
0
ACR70 response is defined as a = 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: physician's global assessment of disease activity (MDG), patient's global assessment of disease activity (PGA), patient's assessment of pain, HAQ-DI and CRP.
Query!
Timepoint [6]
0
0
Weeks 24 and 48
Query!
Secondary outcome [7]
0
0
Percentage of Participants With a Reduction in the HAQ-DI Score
Query!
Assessment method [7]
0
0
Health Assessment Questionnaire - Disability Index (HAQ-DI): The Stanford Health Assessment Questionnaire disability index is a patient reported questionnaire specific for RA. It consists of 20 questions referring to eight component. Reduction in the HAQ-DI score of 0.25 units from baseline to weeks 24 and 48 represented a minimal clinically relevant improvement.
Query!
Timepoint [7]
0
0
Weeks 24 and 48
Query!
Eligibility
Key inclusion criteria
- Adult patients, = 18 years of age
- Rheumatoid arthritis for at least 3 months
- Inadequate response to previous or current treatment with at least one anti-TNF-alpha
agent
- Receiving either leflunomide or methotrexate for = 12 weeks, with a stable dose for
the last 4 weeks
- Swollen joint count (SJC) = 4 (66 joint count) and tender joint count (TJC) = 4 (68
joint count) at screening and baseline.
- CRP = 0.6 mg/dL using a high-sensitivity assay.
- Positive rheumatoid factor or positive anti-CCP antibody or both.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Rheumatic autoimmune disease or inflammatory joint disease, other than RA
- Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/05/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/05/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
836
Query!
Recruitment in Australia
Recruitment state(s)
QLD,WA
Query!
Recruitment hospital [1]
0
0
Sunshine Coast Rheumatology Research Unit - Maroochydore
Query!
Recruitment hospital [2]
0
0
Princess Alexandra Hospital; Rheumatology - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Royal Perth Hospital; Rheumatology - Shenton Park
Query!
Recruitment postcode(s) [1]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
6008 - Shenton Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Delaware
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Georgia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Idaho
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Illinois
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Indiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Iowa
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Kansas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Kentucky
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Louisiana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Maryland
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Massachusetts
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Michigan
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Minnesota
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Mississippi
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Missouri
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Nebraska
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Hampshire
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Jersey
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New York
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
North Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
North Dakota
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Ohio
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Oklahoma
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Oregon
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Pennsylvania
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
South Carolina
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Tennessee
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Texas
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Utah
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Virginia
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Washington
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Wisconsin
Query!
Country [40]
0
0
Argentina
Query!
State/province [40]
0
0
Buenos Aires
Query!
Country [41]
0
0
Argentina
Query!
State/province [41]
0
0
Florencio Varela
Query!
Country [42]
0
0
Belgium
Query!
State/province [42]
0
0
Brugge
Query!
Country [43]
0
0
Belgium
Query!
State/province [43]
0
0
Bruxelles
Query!
Country [44]
0
0
Belgium
Query!
State/province [44]
0
0
Charleroi
Query!
Country [45]
0
0
Belgium
Query!
State/province [45]
0
0
Gent
Query!
Country [46]
0
0
Belgium
Query!
State/province [46]
0
0
Gilly (Charleroi)
Query!
Country [47]
0
0
Belgium
Query!
State/province [47]
0
0
Leuven
Query!
Country [48]
0
0
Belgium
Query!
State/province [48]
0
0
Merksem
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
GO
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
PR
Query!
Country [51]
0
0
Brazil
Query!
State/province [51]
0
0
RJ
Query!
Country [52]
0
0
Brazil
Query!
State/province [52]
0
0
SP
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Alberta
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
British Columbia
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
Manitoba
Query!
Country [56]
0
0
Canada
Query!
State/province [56]
0
0
Ontario
Query!
Country [57]
0
0
Canada
Query!
State/province [57]
0
0
Quebec
Query!
Country [58]
0
0
Canada
Query!
State/province [58]
0
0
Saskatchewan
Query!
Country [59]
0
0
Czechia
Query!
State/province [59]
0
0
Prague
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Bois Guillaume
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Cahors
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Colmar
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Le Mans
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Lille
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Marseille
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Montpellier
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Nice
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Paris
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Aachen
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Berlin
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Duisburg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Frankfurt
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Freiburg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Giessen
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Hagen
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Hannover
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Heidelberg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Köln
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Mainz
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
München
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Osnabrück
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Würzburg
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Budapest
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Debrecen
Query!
Country [85]
0
0
Hungary
Query!
State/province [85]
0
0
Szombathely
Query!
Country [86]
0
0
Israel
Query!
State/province [86]
0
0
Beer Sheva
Query!
Country [87]
0
0
Israel
Query!
State/province [87]
0
0
Beer Yaakov
Query!
Country [88]
0
0
Israel
Query!
State/province [88]
0
0
Kfar Saba
Query!
Country [89]
0
0
Israel
Query!
State/province [89]
0
0
Petach Tikva
Query!
Country [90]
0
0
Israel
Query!
State/province [90]
0
0
Tel Aviv
Query!
Country [91]
0
0
Italy
Query!
State/province [91]
0
0
Emilia-Romagna
Query!
Country [92]
0
0
Italy
Query!
State/province [92]
0
0
Liguria
Query!
Country [93]
0
0
Italy
Query!
State/province [93]
0
0
Lombardia
Query!
Country [94]
0
0
Italy
Query!
State/province [94]
0
0
Toscana
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Aomori
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Fukuoka
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Hiroshima
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Hokkaido
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Hyogo
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Nagasaki
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Osaka
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Saitama
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Shizuoka
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Tochigi
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Tokyo
Query!
Country [106]
0
0
Mexico
Query!
State/province [106]
0
0
Guadalajara
Query!
Country [107]
0
0
Mexico
Query!
State/province [107]
0
0
Mexicali
Query!
Country [108]
0
0
Mexico
Query!
State/province [108]
0
0
Mexico
Query!
Country [109]
0
0
Mexico
Query!
State/province [109]
0
0
Obregon
Query!
Country [110]
0
0
Netherlands
Query!
State/province [110]
0
0
Amsterdam
Query!
Country [111]
0
0
Netherlands
Query!
State/province [111]
0
0
Eindhoven
Query!
Country [112]
0
0
New Zealand
Query!
State/province [112]
0
0
Timaru
Query!
Country [113]
0
0
Panama
Query!
State/province [113]
0
0
Panama City
Query!
Country [114]
0
0
Peru
Query!
State/province [114]
0
0
Callao
Query!
Country [115]
0
0
Peru
Query!
State/province [115]
0
0
Lima
Query!
Country [116]
0
0
Poland
Query!
State/province [116]
0
0
Bydgoszcz
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Elblag
Query!
Country [118]
0
0
Poland
Query!
State/province [118]
0
0
Szczecin
Query!
Country [119]
0
0
Slovakia
Query!
State/province [119]
0
0
Piestany
Query!
Country [120]
0
0
Slovenia
Query!
State/province [120]
0
0
Ljubljana
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Asturias
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Barcelona
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Cadiz
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Cantabria
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
LA Coruña
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Vizcaya
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Badajoz
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Burgos
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Guadalajara
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Madrid
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Salamanca
Query!
Country [132]
0
0
Sweden
Query!
State/province [132]
0
0
Linkoeping
Query!
Country [133]
0
0
Sweden
Query!
State/province [133]
0
0
Uppsala
Query!
Country [134]
0
0
Switzerland
Query!
State/province [134]
0
0
Lausanne
Query!
Country [135]
0
0
Switzerland
Query!
State/province [135]
0
0
Zürich
Query!
Country [136]
0
0
Taiwan
Query!
State/province [136]
0
0
Kaohsiung
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Roche Pharma AG
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in
patients with active rheumatoid arthritis who have an inadequate response to at least one
anti-TNF-alpha therapy. Patients will be randomized to receive placebo, 200mg of intravenous
ocrelizumab, or 500mg of i.v. ocrelizumab on days 1 and 15. A repeat course of i.v. treatment
will be administered at weeks 24 and 26. All patients will receive stable doses of either
concomitant methotrexate (7.5-25mg/week) or leflunomide (10-20mg po daily) and may receive
additional DMARDs. The treatment period is planned for 48 weeks (until primary analysis) and
then participants will enter the open label phase until the drug is commercialized. Target
sample size is 1000.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00476996
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00476996
Download to PDF